Opinion|Videos|September 10, 2024
HMA Persistence and Effectiveness in Higher Risk MDS
Medical experts offer insights on the persistence and effectiveness of HMAs in patients with higher-risk MDS.
Advertisement
Episodes in this series
Video content above is prompted by the following:
What insights do you have on the persistence and effectiveness of hypomethylating agents in patients with higher-risk myelodysplastic syndromes, and how do these data inform treatment decisions?
- Please include a discussion of 65th American Society of Hematology Annual Meeting and Exposition abstract 548 by Zeidan et al.
Advertisement
Related to this article
Claims data show regorafenib is prescribed earlier than guidelines advise for a good share of patients with advanced GIST, with dosing also varying widely.
Vitamin K shot refusals rose 77% from 2017 to 2024. Experts break down the drivers, risks, and how clinicians and payers should respond in 5 FAQs.
Oral GLP-1s, Medicare access, and lingering weight bias are reshaping obesity care, says NYU Langone's Holly Lofton, MD.
Activated memory B cells were already enriched at treatment end in the 5 of 21 patients who later cleared HBsAg
Karen van Caulil, PhD, on how employers can improve cancer care by investing in access, prevention, and support through treatment and survivorship.
Specialty pharmacy leaders will gather in National Harbor for inSPire2026, tackling cell and gene therapy access, AI, and high-cost drug pricing.
Debra Patt, MD, PhD, MBA, MPH, discusses AI adoption, administrative burden, and strategies to streamline prior authorization in oncology.
ERS spotlights AI lung disease detection; employer cancer benefits; outpatient CAR T; tafasitamab response similar across races; HFpEF missed at referral.
Advertisement
Advertisement
Trending on AJMC
1
Delayed Dupilumab Raises Asthma Costs 32%: Nicola Hanania, MD
2
A Patient-Centered Reconstruction of 340B in Oncology: Transparency, Equity, and Site-of-Care Accountability
3
FDA Expands Finerenone Approval to CKD Associated With Type 1 Diabetes
4
Oral GLP-1s, Medicare Bridge Reshape Obesity Care: Holly Lofton, MD
5